ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody

By The Science Advisory Board staff writers

September 17, 2020 -- ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.

Under the agreement, ImmunoPrecise will use Zymeworks' Azymetric and Efect platforms to further develop multiple COVID-19 monospecific antibody candidates by transforming them into bispecific and multispecific antibodies, the companies said.

Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...
Zymeworks, Merck to develop multispecific antibodies
Merck has signed a research and licensing agreement to develop multispecific antibody therapeutic candidates using platforms from clinical-stage biopharmaceutical...
ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...
ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2020 scienceboard.net


Conferences
Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter